A prospective interventional trial on the effect of periodontal treatment on Fusobacterium nucleatum abundance in patients with colorectal tumours

Sci Rep. 2021 Dec 9;11(1):23719. doi: 10.1038/s41598-021-03083-4.

Abstract

Fusobacterium nucleatum is associated with the progression of colorectal cancer. Thus, the possibility of preventing colorectal cancer or its progression by targeting F. nucleatum has been explored. As F. nucleatum is associated with periodontitis, we analysed whether treating periodontitis could influence F. nucleatum abundance in the colon. Patients with colorectal tumours who underwent colonoscopy were recruited. Patients diagnosed with periodontitis by a dentist were treated for approximately 3 months. Endoscopic resection of colorectal tumours was performed after periodontitis treatment, and resected tumours were pathologically classified as high-(HGD) or low-grade dysplasia (LGD). Saliva and stool samples were collected before and after the treatment. Of the 58 patients with colorectal tumours, 31 were included in the study, 16 showed improvement in periodontitis, and 11 showed no improvement. Stool F. nucleatum levels before treatment were significantly lower in the LGD group than in the HGD group. A significant decrease in faecal F. nucleatum levels was observed in patients who underwent successful treatment but not in those whose treatment failed. Salivary F. nucleatum levels were not altered in patients despite periodontal treatment. Thus, successful periodontitis treatment reduces stool F. nucleatum levels and may aid research on periodontitis and suppression of colorectal cancer development.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Load
  • Colorectal Neoplasms / complications*
  • Comorbidity
  • Disease Management
  • Disease Susceptibility
  • Feces / microbiology
  • Female
  • Fusobacterium Infections / drug therapy*
  • Fusobacterium Infections / etiology*
  • Fusobacterium nucleatum*
  • Gastrointestinal Microbiome / drug effects
  • Humans
  • Male
  • Middle Aged
  • Periodontitis / drug therapy*
  • Periodontitis / etiology*
  • Saliva / microbiology
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents